Article
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
Pharmacogenetics and genomics - 1 Oct 2010
Kaspera Rüdiger, Naraharisetti Suresh B, Tamraz Bani, Sahele Tariku, Cheesman Matthew J, Kwok Pui-Yan, Marciante Kristin, Heckbert Susan R, Psaty Bruce M, Totah Rheem A
Abstract excerpt
OBJECTIVES: Cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.